Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable ...

An international team led by Monash University researchers has uncovered the genetic code governing the way genetic mutations affect mRNA and result in disease.

The UC Santa Cruz RNA Center hosted a premiere screening of “Cracking the Code: Phil Sharp and the Biotech Revolution” at the ...

The mRNA therapeutics market offers key opportunities in developing vaccines and treatments for chronic and infectious diseases, driven by successful clinical trials and increased government and ...

MRNA acts as the key intermediate between DNA, the genetic blueprint, and proteins that carry out most of the work in cells, with RNA splicing ensuring proper reading of the blueprint by removing some ...

Alternative splicing exhibits lineage-specific variability, with mammals and birds reaching the highest levels despite conserved intron-rich architectures, while unicellular eukaryotes and prokaryotes ...

Key pointsMonash researchers have uncovered the hidden 'code' governing how genetic mutations affect RNA splicing and result in diseaseBreakthrough ...

Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring treatment response and progression-free survival in ...

Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing ...

Significant advancements in gene silencing and gene editing offer new hope for treating rare disorders. Techniques like RNA ...

New research has shown that nanobody treatments that block PD-L1 can reduce tumor growth by about 50% in cancers that don't ...

E. John Wherry, director of Penn's Colton Center for Autoimmunity, spoke with the Inquirer about the future of immunology ...